GBS Inc. is a biosensor diagnostic technology company. The Company develops and commercializes a range of biosensor-based point of care (POCT) diagnostic tests that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens and endocrinology. Its flagship product candidate is the Saliva Glucose Biosensor (SGB), a POCT designed to substitute the finger pricking invasive blood glucose monitoring for diabetic patients. SGB uses saliva to measure glucose non-invasively. When the SGB interacts with saliva, an electrochemical reaction is initiated that produces an electrical signal directly correlated to the amount of glucose present in the saliva. This measurement is then converted into a real-time saliva glucose reading by a software application on a smart device or a dedicated smart reader. The Company is also developing a real-time SARS-CoV-2 antibody biosensor.
No company officers listed.
During the most recent quarter, 840 shares were bought in insider trading.
Insider trading information report provided by Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.